Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2022-04-15 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding abnormal stock price fluctuations of Zhejiang Tailin Biotechnology Co., Ltd. It explains the situation, confirms no undisclosed material information, and provides risk warnings to investors. The text does not contain financial statements, audit information, or detailed financial results. It is a regulatory disclosure about stock trading behavior and compliance with stock exchange rules. The document length is short (1508 characters) and it is an announcement rather than a report. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2022-04-15 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding abnormal stock price fluctuations of Zhejiang Tailin Biotechnology Co., Ltd. It explains the reasons behind the stock price volatility, including recent product developments, production impacts due to COVID-19, and risk warnings to investors. The document does not contain financial statements, audit information, or detailed financial results. It is a regulatory disclosure about stock trading behavior and company status rather than a financial report or management discussion. The document length is 2216 characters, which is relatively short and consistent with a regulatory announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-04-01 Chinese
关于公司受疫情影响临时停工停产园区复工复产的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding temporary suspension and resumption of production due to COVID-19 related government restrictions. It includes details about the dates of shutdown and reopening, references to prior announcements, and assurances about compliance and risk management. The document is short (817 characters) and does not contain financial statements, earnings data, or detailed financial analysis. It is an operational update related to pandemic impact rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is also not a voting result, board change, or capital update. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2022-03-20 Chinese
中证鹏元关于关注浙江泰林生物技术股份有限公司滨江园区受疫情影响临时停工停产的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a credit rating agency (中证鹏元资信评估股份有限公司) regarding the temporary suspension of production at a company's facility due to COVID-19 impact. It includes credit rating information and the expected impact on the company's operations and financials. The document is short (1184 characters) and serves as an update on credit rating and operational status rather than a full financial report or audit. It does not contain detailed financial statements or comprehensive management discussion. It is not an earnings release, annual report, or interim report. It is a regulatory announcement related to credit rating and operational impact, fitting best under Regulatory Filings (RNS).
2022-03-16 Chinese
长城证券股份有限公司关于浙江泰林生物技术股份有限公司持续督导之2021年度培训情况总结
Regulatory Filings Classification · 95% confidence The document is a summary report of a training session conducted by the sponsor (长城证券股份有限公司) for the board, supervisors, senior management, and controlling shareholders of 浙江泰林生物技术股份有限公司. It details the training process, participants, content, and outcomes related to continuous supervision in 2021. The document references regulatory requirements and internal governance training but does not contain financial statements, earnings data, or audit results. It is not an announcement of a report publication but a summary of a specific training event. This type of document fits best under Regulatory Filings (RNS) as it is a compliance-related report that does not fall into other specific categories like Annual Report, Management Report, or Governance Information. The document length is short (1754 characters), and it is a detailed summary rather than a brief announcement, so RNS is appropriate rather than RPA.
2022-03-10 Chinese
长城证券股份有限公司关于浙江泰林生物技术股份有限公司2021年度定期现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "持续督导定期现场检查报告" which translates to "Continuous Supervision Regular On-site Inspection Report" by the sponsor Great Wall Securities Co., Ltd. for Zhejiang Tailin Biotechnology Co., Ltd. It details the findings of an on-site inspection covering governance, internal control, information disclosure, use of raised funds, performance, and other compliance matters for the 2021 fiscal year. The document includes detailed compliance checks, audit committee activities, and observations about financial and operational matters, but it is not a full annual report or audit report by itself. It is a regulatory compliance inspection report by the sponsor, which fits best under Audit Report / Information (AR) as it relates to audit and regulatory inspection results rather than a full annual report or other categories. The document length is 3709 characters, which is substantive and contains detailed findings, not just an announcement or certification. Therefore, the best classification is AR with high confidence. FY 2021
2022-03-10 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.